Introduction: The International Association for the Study of Lung Cancer recently proposed new M descriptors for the next edition of the TNM classification for NSCLC, subdividing the current M1b category into two subcategories: M1b, which indicates a solitary extrathoracic metastasis in a single organ, and M1c, which indicates multiple extrathoracic metastasis. The purpose of this study was to validate the prognostic value of the newly proposed M descriptors in an independent cohort with multivariate and subgroup analysis.
Introduction
The seventh edition of TNM classification for lung cancer incorporated patients with pleural disseminationformerly categorized as T4-into the new M category and enabled differential prognostication of metastatic NSCLC with two M descriptors, namely, M1a and M1b. 1 This revision was based on findings from a large database, which showed that median overall survival (OS) of patients with malignant pleural effusion alone was significantly shorter than that of other cT4M0 cases but comparable to the OS of patients with contralateral lung metastasis. 2 However, the seventh edition did not reflect the prognostic impact of the number and locations of distant metastasis owing to the lack of detailed information. 3 As novel diagnostic modalities such as whole body 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography-computed tomography (PET-CT) and video-assisted thoracoscopy have been increasingly adopted into clinical practice, the sensitivity of detecting small lesions has been improved. 4, 5 Novel local treatment modalities, including stereotactic body radiation therapy, stereotactic radiosurgery (SRS), and metastatectomy using video-assisted thoracic surgery or laparoscopy, have led to better local control in stage IV NSCLC. [6] [7] [8] [9] [10] [11] Furthermore, molecular targeted agents, including EGFR tyrosine kinase inhibitor (TKI) and anaplastic lymphoma kinase (ALK) inhibitor, have resulted in a substantial improvement in the outcome of EGFR/ALK-positive NSCLC. [12] [13] [14] In 2015, the International Association for the Study of Lung Cancer (IASLC) proposed new criteria for TNM classification of lung cancer on the basis of a new database composed of 94,708 cases diagnosed between 1999 and 2010. 15 With these and other cases collected through an electronic data capture system until 2012, a total of 1059 NSCLC cases were used to analyze the prognostic impact of distant metastasis and finally propose reclassification of the two current M categories (M1a and M1b) into three (M1a, M1b, and M1c). 16 According to these criteria, patients in the category M1a remain in the same stage according to the current classification system, whereas those with a single extrathoracic metastatic lesion in a single organ or multiple extrathoracic metastatic lesions are separately classified into M1b and M1c, respectively. However, this proposal was based only on univariate analysis using limited clinical information of individual patients, and no external validation has been presented. To address this issue, we analyzed a consecutive retrospective singleinstitute NSCLC cohort database with multivariable adjustment and subgroup analysis. The purpose of this study was to externally validate the prognostic value of the newly proposed M staging.
Patients and Methods

Eligible Patients and Data Collection
Patients in whom stage IV NSCLC was diagnosed between January 1, 2011, and December 31, 2014, in Seoul National University Hospital (SNUH) were included in this study. Eligibility criteria included (1) pathologically confirmed clinical stage IV NSCLC according to the seventh edition of anatomical staging system for lung cancer and (2) available pretreatment FDG PET-CT results. Patients whose disease was initially diagnosed as stage I, II, or III NSCLC that progressed into a metastatic disease or relapsed were excluded. Subjects were selected in a registry of consecutively collected patients with cancer, including all patients with NSCLC who had been treated with palliative chemotherapy in SNUH since 2011. EGFR mutations were detected by a direct sequencing method 17 and the peptide nucleic acid clamping method. 18 Anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements were detected with use of a previously described method. 19 
M Stage Description
All FDG PET-CT and brain magnetic resonance imaging (MRI) reports were reviewed to classify each patient into one of three M categories in blinded fashion with respect to survival data. For patients in the category M1b (those with a single-organ single extrathoracic metastasis), the organ of metastasis and whether metastatectomy or SRS was performed before any systemic treatment were recorded by reviewing surgical records. Patients without definite distant metastatic lesions, except pleural or pericardial effusion, were classified as M1a if the effusion contained cytologically confirmed malignant cells or cells highly likely to be malignant in terms of the clinical situation, amount, unilaterality, and routine cell count profile. In cases of pleural effusion too small to warrant cytological evaluation, radiologically observed pleural thickening, nodularity, or FDG avidity was considered to be a metastatic disease if highly suspicious radiologically. Cervical (outside the supraclavicular region), axillary, subpectoral, internal mammary, intercostal, diaphragmatic, and abdominal nodal group involvement were considered to be metastatic lesions.
Statistical Analysis
Categorical variables were analyzed by using chisquare tests or Fisher's exact tests, where appropriate. Either one-way analysis of variance or the Kruskal-Wallis equality-of-populations rank tests were used for continuous variables according to the normality of data assessed with Shapiro-Wilk tests and quantile-quantile plots. OS was defined as the interval from the date of diagnosis to death from any cause. The Kaplan-Meier method was used to estimate OS. Nonparametric comparisons of survival curves were performed with log-rank tests and Wilcoxon-BreslowGehan tests. Cox proportional hazards regression analysis was used to construct univariate and multivariate models. For the multivariate model, Cramer's V was calculated to check the correlation between each covariate and exclude highly correlated variables, namely, those with Cramer's V greater than 0.3, from the model to avoid multicollinearity. To check the validity of the proportional hazards assumption, scaled Schoenfeld residuals were plotted versus time for each M descriptor, and the resulting locally weighted scatterplot smoothing curves were tested for nonzero slopes with algorithms developed by Grambsch and Therneau. 20 Adjusted survival curves were visualized by using the multivariate Cox proportional hazards model (Cox model) by pooling the estimated survival curves over strata of combinations of each level of the covariates in weighted fashion on the basis of the marginal distribution of the covariates. 21 All tests were two sided, and p values less than 0.05 were considered statistically significant. STATA Statistical Software version 12.0 (StataCorp LP, College Station, Texas) was used for computation. 
Ethical Issues
The institutional review board of SNUH approved the study protocol (institutional review board approval number H-1601-065-734). All procedures were carried out in accordance with the ethical standards of the institutional research ethics committee and the Helsinki Declaration revised in the 2013 World Medical Association.
Results
Patient Characteristics
A total of 1024 patients were analyzed. FDG PET-CT was performed for all patients, and brain MRI was performed for 818 patients (79.9%) as an initial staging evaluation. According to the IASLC M descriptors, 262 patients (25.6%), 152 patients (14.8%), and 610 patients (59.6%) were classified into the subgroups M1a, M1b, and M1c, respectively. Characteristics of the entire patient cohort and each M category are summarized in Table 1 . The disease of patients in the M1a group was diagnosed when they were at relatively advanced ages, whereas those in the M1c group had initially poor performance. Adenocarcinoma was the most common pathologic subtype overall and accounted for a larger percentage patients in the M1c category than in the M1a and M1b categories, which is in accordance with the high proportion of ALK gene rearrangements in this subset of patients. Among patients in the M1b group, the most common site of metastasis was bone, followed by the brain. Radical treatment for metastatic lesions was performed before systemic treatment for 24 patients (64.9%) with a solitary brain metastatic tumor, whereas it was performed for only five patients (4.4%) with a single metastatic lesion in other organs in the M1b group. The 24 cases of radical treatment for brain metastasis included surgical tumor removal for five patients (20.8%) and SRS for the remaining 19 patients (79.2%).
Survival Discrimination of Newly Proposed M Descriptors
With a median follow-up duration of 42.2 months, 820 deaths occurred in the entire cohort. The unadjusted Kaplan-Meier survival curve for OS is shown in Figure 1A cytotoxic chemotherapy versus with EGFR TKIs or ALK inhibitors. Five covariates, excluding multicollinearity, were selected to fit a multivariate Cox model for the entire cohort, namely, age at diagnosis, Eastern Cooperative Oncology Group performance status, pathologic subtype, molecular subtype, and newly proposed M descriptors. Sex, smoking status, and overall treatment regimen was excluded from fitting the model owing to high correlation with the molecular subtype (Cramer's V ¼ 0.358, 0.354, and 0.649, respectively). The adjusted HRs with the corresponding 95% CI for each predictor are summarized in Table 2 . After adjustment for other covariates, a statistically significant reduction in OS was observed for the M1b group versus for the M1a group (HR ¼ 1.30, 95% CI: 1.03-1.65, p ¼ 0.03) and the M1c group versus the M1b group (HR ¼ 1.57, 95% CI: 1.28-1.93, p < 0.001). The adjusted survival curve for each M descriptor is shown in Figure 2A . All included covariates were statistically significant survival predictors in the multivariate model, except for the comparison between Eastern Cooperative Oncology Group performance status 0 and 1. The test for nonzero slope of the locally weighted scatterplot smoothing curve fit to Schoenfeld residuals for each M category indicator ( Supplementary  Figs. 1 and 2 ) and the adjusted log minus log survival plot versus log of survival time ( Supplementary Fig. 3 ) indicated no significant violation of the proportional hazards assumption.
Subgroup Analysis
Differences in baseline characteristics among patients with each pathologic and molecular subtype are summarized in Supplementary Tables 1 and 2 , respectively. We conducted subgroup analysis to investigate survival discrimination of the newly suggested M descriptors in each subset of patients according to these features (Fig. 1B-D) and those having received brain MRI as an initial staging evaluation (Fig. 2B ). Univariate HRs with corresponding 95% CIs are summarized in Figure 3 . The M1b category showed a tendency toward shorter survival compared with the M1a category in all subgroups except the ALK-translocated subset. A consistent tendency toward superior outcome for the M1b category than for the M1c category was observed in all subgroups.
In the subgroup univariate Cox model for patients in the M1a group, those with pleural nodules showed a superior survival compared with those with contralateral lung metastasis (Fig. 4A) . However, this difference in survival was not evident after adjustment for other covariates (Table 2 ). For the M1b group, no prognostic impact was observed according to the site of metastasis (Fig. 4B ) or according to whether radical treatment for the metastatic lesion was performed before systemic treatment in either univariate or multivariate analysis ( Table 2 ).
Discussion
Our study validated survival discrimination of the newly proposed M descriptors in the latest IASLC report in which cases in the category M1c, which was separated from the former category M1b, were associated with a significantly poorer prognosis than other M1b cases. 16 The prognostic value of the newly suggested M descriptors remained consistent after adjustment for other clinical prognostic factors, regardless of the pathologic and molecular subtypes.
Distinguishing M1b from M1c is clinically important because (1) M1b tends to show a better OS than M1c and (2) a favorable prognostic subset of patients may exist within the M1b group that has suitable local treatments for both the primary and metastatic lesions. Aggressive treatment for patients with oligometastatic stage IV lung cancer has been shown to be associated with a favorable outcome. [22] [23] [24] [25] [26] [27] However, our data cannot confirm the role of a radical treatment approach for the metastatic lesion in the M1b group. This could be due to the heterogeneity of metastatic organs in the M1b group and low statistical power owing to the small sample size. As previous reports regarding this issue were also based on a small number of cases and retrospectively analyzed data, 22, 24, 26, 27 a well-organized prospective trial is necessary to draw a reliable conclusion for this issue.
In the IASLC report, the prognostic impact of each M1a descriptor and the site and number of distant metastatic lesions were investigated in depth, revealing no consistent evidence to support further separation of stage IV NSCLC from the newly suggested classification of M1a, M1b, and M1c. 16 From our data, prognosis according to metastatic sites in the M1b group failed to show any statistically significant difference between groups. Inconsistent results were also obtained regarding the influence on survival of each M1a descriptor in univariate and multivariate analysis. Patients with pleural nodules seemed to survive longer than other groups, but this difference in survival was not statistically significant in the multivariate analysis. As in the IASLC database, the numbers of M1a and M1b cases were too small to conclude anything in the organ-specific analysis. Future investigations with larger study sample sizes are necessary to draw firm conclusions concerning this topic.
This study has several limitations. First, this study is based on retrospective data. Data regarding comorbidities were not included for multivariate analysis owing to lack of detailed information. As NSCLC shares important risk factors with cardiovascular and chronic pulmonary diseases, such as old age and smoking, additional adjustment for comorbidities may have caused differences in some of the results of survival analysis. However, as the analyzed cases were selected with predefined eligibility criteria from a consecutively collected database, the possibility of selection bias was minimized. Second, the database was restricted to the "treatment registry" and not the "diagnosis registry," which therefore excluded patients who did not receive palliative chemotherapy for lung cancer owing to poor performance, severe comorbidities, or refusal of palliative chemotherapy. Third, the number of patients with ALK translocation was relatively small due to its low incidence, resulting in a low statistical power in survival comparisons between the three M categories in the subgroup analysis.
Despite these limitations, this study is the first report of external validation of newly proposed M descriptors by using a comprehensive clinical database enabling adjustment for multiple important clinical variables. All patients analyzed in our study received FDG PET-CT as a part of the initial staging evaluation, and they were classified in blinded fashion with respect to survival data. They were therefore less affected by information bias. The role of FDG PET-CT in detecting small metastatic lesions is reflected in the small proportions of M1a and M1b in our data (26% and 15%, respectively) compared with those in the IASLC database (32% and 22%, respectively). 16 In addition, subgroup analysis according to pathologic subtypes, EGFR activating mutations, and ALK gene rearrangements revealed overall consistency of the results. Although brain MRI was not initially conducted in one-fifth of the cohort, univariate and multivariate HRs were similar in those with initial brain MRI results, showing the robustness of our study result. As the eligibility criteria restricted the studied population to those patients treated in the era of EGFR TKIs and ALK inhibitors, the newly suggested M staging can be reliably applied to patients with NSCLC treated with these molecular targeted therapies.
In conclusion, our study externally validated the revision of M descriptors for the next edition of TNM classification of NSCLC. Considering the importance of both appropriate selection of patients who may benefit from local treatment in stage IV NSCLC and development of an optimal treatment strategy for this subset of patients with a solitary metastasis, discrimination of M1b and M1c is crucial and necessary.
